secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001213900-23-043545
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma receives Nasdaq deficiency letter for low stockholders' equity
-----------------------------------------------------------------------------

- Stockholders' equity of $1.73M as of March 31, 2023, below Nasdaq's $2.5M minimum.
- Company has until July 10, 2023 to submit compliance plan; possible extension to Dec 11, 2023.
- No immediate effect on trading; common stock continues on Nasdaq under symbol ABVC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/0001213900-23-043545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/ea179215-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-043545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer